About vamorolone
Dissociative corticosteroid anti-inflammatory
Used for
- Treatment of Duchenne muscular dystrophy in patients aged 2 years and older
Usual adult dose
Not established for adults; approved dosing is for children aged 2 years and older.
Usual dose in children
2 mg/kg by mouth once daily; may increase to 6 mg/kg daily if response is inadequate. Maximum 300 mg daily.
Common side effects
- Cushingoid appearance
- Weight gain
- Vomiting
- Irritability
Important warnings
- May suppress adrenal function; taper after prolonged treatment.
- Increased infection risk; live vaccines may be unsuitable during treatment.
- May affect growth, bone health, blood pressure, and blood sugar.
- Avoid abrupt discontinuation after long-term use.
Pregnancy
Human pregnancy data are limited; use only when potential benefits justify potential fetal risk.
Breastfeeding
It is unknown whether vamorolone passes into breast milk; effects on a nursing infant are unknown.
Interactions
- Strong CYP3A4 inhibitors can increase vamorolone exposure; dose reduction may be needed.
- Strong CYP3A4 inducers can reduce exposure and may lessen treatment effect.
- May reduce immune response to vaccines; avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.